Furthermore, the complete remission rate of low-dose IL-2-treated lupus nephritis patients was also significantly higher at both weeks 12 and 24, while IL-2-treated individuals had reduced 24-hour proteinuria in contrast to the placebo group (21). The gene discussed is IL2; the disease is lupus nephritis.